{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:20:57Z","timestamp":1792718457056,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100016239","name":"University of Occupational and Environmental Health, Japan","doi-asserted-by":"crossref","award":["#19K17919"],"award-info":[{"award-number":["#19K17919"]}],"id":[{"id":"10.13039\/100016239","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40744-025-00762-w","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T03:51:01Z","timestamp":1745207461000},"page":"561-580","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Real-World Safety and Efficacy of Targeted Therapies in Rheumatoid Arthritis: A 5-Year, 5130-Case Follow-Up from FIRST Registry"],"prefix":"10.1007","volume":"12","author":[{"given":"Koshiro","family":"Sonomoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Nakayamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nagayasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"issue":"10","key":"762_CR1","first-page":"591","volume":"18","author":"A Finckh","year":"2022","unstructured":"Finckh A, Gilbert B, Hodkinson B, et al. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022;18(10):591\u2013602.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"762_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/mr\/roac017","volume":"33","author":"Y Kawahito","year":"2023","unstructured":"Kawahito Y, Morinobu A, Kaneko Y, et al. Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication. Mod Rheumatol. 2023;33(1):21\u201335.","journal-title":"Mod Rheumatol"},{"issue":"7","key":"762_CR3","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108\u201323.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"762_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landewe RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"762_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14397595.2019.1660028","volume":"30","author":"H Yamanaka","year":"2020","unstructured":"Yamanaka H, Tanaka E, Nakajima A, et al. A large observational cohort study of rheumatoid arthritis, IORRA: providing context for today\u2019s treatment options. Mod Rheumatol. 2020;30(1):1\u20136.","journal-title":"Mod Rheumatol"},{"key":"762_CR6","unstructured":"Ministry of Health LaWoJ. Annual Report on the Aging Society. 2008."},{"issue":"4","key":"762_CR7","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/art.41571","volume":"73","author":"S Safiri","year":"2021","unstructured":"Safiri S, Kolahi AA, Cross M, et al. Prevalence, deaths, and disability-adjusted life years due to musculoskeletal disorders for 195 countries and territories 1990\u20132017. Arthritis Rheumatol. 2021;73(4):702\u201314.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"762_CR8","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1007\/s10067-024-07083-3","volume":"43","author":"H Gu","year":"2024","unstructured":"Gu H, Yan D, Li J, Long X, Wang K. Trends and future projections of incidence rate and mortality of rheumatoid arthritis in China: a systematic analysis based on GBD 2021 data. Clin Rheumatol. 2024;43(9):2799\u2013806.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"762_CR9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/1756-185X.12998","volume":"20","author":"E Kato","year":"2017","unstructured":"Kato E, Sawada T, Tahara K, et al. The age at onset of rheumatoid arthritis is increasing in Japan: a nationwide database study. Int J Rheum Dis. 2017;20(7):839\u201345.","journal-title":"Int J Rheum Dis"},{"issue":"12","key":"762_CR10","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1111\/1756-185X.13974","volume":"23","author":"A Nakajima","year":"2020","unstructured":"Nakajima A, Sakai R, Inoue E, Harigai M. Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Int J Rheum Dis. 2020;23(12):1676\u201384.","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"762_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0286191","volume":"18","author":"M Zhang","year":"2023","unstructured":"Zhang M, Yin J, Zhang X. Factors associated with interstitial lung disease in patients with rheumatoid arthritis: a systematic review and meta-analysis. PLoS ONE. 2023;18(6): e0286191.","journal-title":"PLoS ONE"},{"issue":"10","key":"762_CR12","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1093\/rheumatology\/kead075","volume":"62","author":"H Miyata","year":"2023","unstructured":"Miyata H, Sonomoto K, Fukuyo S, et al. Computed tomography for malignancy screening in patients with rheumatoid arthritis before initiation of disease-modifying antirheumatic drug. Rheumatology (Oxford). 2023;62(10):3339\u201349.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"762_CR13","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s40744-023-00603-8","volume":"10","author":"S Kubo","year":"2023","unstructured":"Kubo S, Miyazaki Y, Todoroki Y, et al. Generation-dependent retention rates and reasons for discontinuation of molecular targeted therapies in patients with rheumatoid arthritis: from FIRST registry. Rheumatol Ther. 2023;10(6):1705\u201323.","journal-title":"Rheumatol Ther"},{"issue":"3","key":"762_CR14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s40744-024-00668-z","volume":"11","author":"K Sonomoto","year":"2024","unstructured":"Sonomoto K, Fujino Y, Tanaka H, et al. A machine learning approach for prediction of CDAI remission with TNF inhibitors: a concept of precision medicine from the FIRST registry. Rheumatol Ther. 2024;11(3):709\u201336.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"762_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/14397595.2020.1847775","volume":"32","author":"K Nakano","year":"2022","unstructured":"Nakano K, Tanaka Y, Saito K, et al. Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study. Mod Rheumatol. 2022;32(1):41\u20139.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"762_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1136\/ard-2022-222543","volume":"82","author":"JR Curtis","year":"2023","unstructured":"Curtis JR, Yamaoka K, Chen YH, et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023;82(3):331\u201343.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"762_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39\u201352.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"762_CR18","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/rheumatology\/keab647","volume":"61","author":"K Sonomoto","year":"2022","unstructured":"Sonomoto K, Tanaka H, Nguyen TM, et al. Prophylaxis against pneumocystis pneumonia in rheumatoid arthritis patients treated with b\/tsDMARDs: insights from 3787 cases in the FIRST registry. Rheumatology (Oxford). 2022;61(5):1831\u201340.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"762_CR19","doi-asserted-by":"publisher","first-page":"86","DOI":"10.55563\/clinexprheumatol\/g33ia5","volume":"40","author":"S Ochi","year":"2022","unstructured":"Ochi S, Mizoguchi F, Nakano K, Tanaka Y. Difficult-to-treat rheumatoid arthritis with respect to responsiveness to biologic\/targeted synthetic DMARDs: a retrospective cohort study from the FIRST registry. Clin Exp Rheumatol. 2022;40(1):86\u201396.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"762_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/BOR.0b013e3282f51031","volume":"20","author":"AK McDonough","year":"2008","unstructured":"McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol. 2008;20(2):131\u20137.","journal-title":"Curr Opin Rheumatol"},{"issue":"10","key":"762_CR21","doi-asserted-by":"publisher","first-page":"764","DOI":"10.7326\/0003-4819-141-10-200411160-00007","volume":"141","author":"L Wei","year":"2004","unstructured":"Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141(10):764\u201370.","journal-title":"Ann Intern Med"},{"issue":"2","key":"762_CR22","doi-asserted-by":"publisher","first-page":"e004049","DOI":"10.1136\/rmdopen-2023-004049","volume":"10","author":"M Funada","year":"2024","unstructured":"Funada M, Miyazaki Y, Nakayamada S, et al. CT informs detection and treatment options in rheumatoid arthritis complicated by pulmonary non-tuberculous mycobacterial disease from the FIRST registry. RMD Open. 2024;10(2):e004049. https:\/\/doi.org\/10.1136\/rmdopen-2023-004049.","journal-title":"RMD Open"},{"issue":"7","key":"762_CR23","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1136\/ard.2005.043166","volume":"65","author":"MH Schiff","year":"2006","unstructured":"Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(7):889\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"762_CR24","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/rheumatology\/key023","volume":"57","author":"AI Rutherford","year":"2018","unstructured":"Rutherford AI, Patarata E, Subesinghe S, Hyrich KL, Galloway JB. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology (Oxford). 2018;57(6):997\u20131001.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"762_CR25","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s10067-019-04516-2","volume":"38","author":"R Ranza","year":"2019","unstructured":"Ranza R, de la Vega MC, Laurindo IMM, et al. Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR. Clin Rheumatol. 2019;38(8):2129\u201339.","journal-title":"Clin Rheumatol"},{"issue":"1","key":"762_CR26","doi-asserted-by":"publisher","first-page":"e001174","DOI":"10.1136\/rmdopen-2020-001174","volume":"6","author":"A Finckh","year":"2020","unstructured":"Finckh A, Tellenbach C, Herzog L, et al. Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland. RMD Open. 2020;6(1):e001174. https:\/\/doi.org\/10.1136\/rmdopen-2020-001174.","journal-title":"RMD Open"},{"issue":"1","key":"762_CR27","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13075-021-02496-w","volume":"23","author":"S Jinno","year":"2021","unstructured":"Jinno S, Onishi A, Dubreuil M, et al. Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study. Arthritis Res Ther. 2021;23(1):116.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"762_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/rheumatology\/keac285","volume":"62","author":"A Amstad","year":"2022","unstructured":"Amstad A, Papagiannoulis E, Scherer A, et al. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy. Rheumatology (Oxford). 2022;62(1):89\u201397.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"762_CR29","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1136\/annrheumdis-2022-222586","volume":"81","author":"K Lauper","year":"2022","unstructured":"Lauper K, Iudici M, Mongin D, et al. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31,846 patients with rheumatoid arthritis in 19 registers from the \u201cJAK-pot\u201d collaboration. Ann Rheum Dis. 2022;81(10):1358\u201366.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"762_CR30","doi-asserted-by":"publisher","first-page":"e003160","DOI":"10.1136\/rmdopen-2023-003160","volume":"9","author":"K Ebina","year":"2023","unstructured":"Ebina K, Etani Y, Maeda Y, et al. Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study. RMD Open. 2023;9(3):e003160. https:\/\/doi.org\/10.1136\/rmdopen-2023-003160.","journal-title":"RMD Open"},{"issue":"11","key":"762_CR31","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1093\/rheumatology\/kead620","volume":"63","author":"A Onishi","year":"2024","unstructured":"Onishi A, Yamada H, Yamamoto W, et al. Comparative effectiveness of biological disease-modifying antirheumatic drugs and Janus kinase inhibitor monotherapy in rheumatoid arthritis. Rheumatology (Oxford). 2024;63(11):3065\u201373.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"762_CR32","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1093\/rheumatology\/keae081","volume":"64","author":"S Jinno","year":"2025","unstructured":"Jinno S, Onishi A, Hattori S, et al. Comparison of retention of biologics in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study. Rheumatology (Oxford). 2025;64(2):509\u201316.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"762_CR33","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/ckj\/sfac036","volume":"15","author":"H Hanaoka","year":"2022","unstructured":"Hanaoka H, Kikuchi J, Hiramoto K, et al. Decreased chronic kidney disease in rheumatoid arthritis in the era of biologic disease-modifying anti-rheumatic drugs. Clin Kidney J. 2022;15(7):1373\u20138.","journal-title":"Clin Kidney J"},{"issue":"2","key":"762_CR34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/ard-2024-226156","volume":"84","author":"S Fukui","year":"2025","unstructured":"Fukui S, Winkelmayer WC, Tedeschi SK, et al. Disease activity of rheumatoid arthritis and kidney function decline: a large prospective registry study. Ann Rheum Dis. 2025;84(2):201\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"762_CR35","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3899\/jrheum.161235","volume":"44","author":"MLE Andersson","year":"2017","unstructured":"Andersson MLE, Forslind K, Hafstrom I, Group BS. Patients with early rheumatoid arthritis in the 2000s have equal disability and pain despite less disease activity compared with the 1990s: data from the BARFOT study over 8 years. J Rheumatol. 2017;44(6):723\u201331.","journal-title":"J Rheumatol"},{"issue":"6","key":"762_CR36","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.mayocp.2019.01.002","volume":"94","author":"E Myasoedova","year":"2019","unstructured":"Myasoedova E, Davis JM 3rd, Achenbach SJ, Matteson EL, Crowson CS. Trends in prevalence of functional disability in rheumatoid arthritis compared with the general population. Mayo Clin Proc. 2019;94(6):1035\u20139.","journal-title":"Mayo Clin Proc"},{"key":"762_CR37","unstructured":"World O, Data i. Burden of Disease [Available from: https:\/\/ourworldindata.org\/burden-of-disease. Accessed 13 Jan 2025."},{"issue":"7","key":"762_CR38","first-page":"1516","volume":"41","author":"W Yang","year":"2023","unstructured":"Yang W, Xu Y, Lin J, et al. Global, regional and national burden of rheumatoid arthritis, and attributable risk factors from 1990 to 2019: update from the Global Burden of Disease 2019 study. Clin Exp Rheumatol. 2023;41(7):1516\u201327.","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"762_CR39","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1136\/annrheumdis-2015-209058","volume":"76","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Lu N, Peloquin C, et al. Improved survival in rheumatoid arthritis: a general population-based cohort study. Ann Rheum Dis. 2017;76(2):408\u201313.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"762_CR40","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1093\/rheumatology\/kead325","volume":"63","author":"BG Soussi","year":"2024","unstructured":"Soussi BG, Duch K, Cordtz RL, et al. Temporal trends in mortality in patients with rheumatoid arthritis: a Danish population-based matched cohort study. Rheumatology (Oxford). 2024;63(4):1049\u201357.","journal-title":"Rheumatology (Oxford)"},{"key":"762_CR41","doi-asserted-by":"publisher","first-page":"3878953","DOI":"10.1155\/2018\/3878953","volume":"2018","author":"R Caporali","year":"2018","unstructured":"Caporali R, Doria A, Ferraccioli GF, et al. Unmet needs in the treatment of RA in the Era of Jak-i: IDRA (Italian Delphi Rheumatoid Arthritis) consensus. Biomed Res Int. 2018;2018:3878953.","journal-title":"Biomed Res Int"},{"issue":"1","key":"762_CR42","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12955-019-1127-8","volume":"17","author":"DT Boumpas","year":"2019","unstructured":"Boumpas DT, Sidiropoulos P, Settas L, et al. Health outcomes and unmet needs in patients with long-standing rheumatoid arthritis attending tertiary care in Greece: a cohort study. Health Qual Life Outcomes. 2019;17(1):73.","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"762_CR43","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/art.20048","volume":"50","author":"E Krishnan","year":"2004","unstructured":"Krishnan E, Sokka T, Hakkinen A, Hubert H, Hannonen P. Normative values for the Health Assessment Questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum. 2004;50(3):953\u201360.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"762_CR44","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13075-024-03369-8","volume":"26","author":"S Ochi","year":"2024","unstructured":"Ochi S, Sonomoto K, Nakayamada S, Tanaka Y. Predictors of functional improvement and pain reduction in rheumatoid arthritis patients who achieved low disease activity with disease-modifying antirheumatic drugs: a retrospective study of the FIRST Registry. Arthritis Res Ther. 2024;26(1):140.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"762_CR45","doi-asserted-by":"publisher","first-page":"e002111","DOI":"10.1136\/rmdopen-2021-002111","volume":"8","author":"P Hanlon","year":"2022","unstructured":"Hanlon P, Morton F, Siebert S, et al. Frailty in rheumatoidrmdopen-2021-002111 arthritis and its relationship with disease activity, hospitalisation and mortality: a longitudinal analysis of the Scottish Early Rheumatoid Arthritis cohort and UK Biobank. RMD Open. 2022;8(1):e002111. https:\/\/doi.org\/10.1136\/rmdopen-2021-002111.","journal-title":"RMD Open"},{"issue":"2","key":"762_CR46","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40744-017-0072-4","volume":"4","author":"MH Withers","year":"2017","unstructured":"Withers MH, Gonzalez LT, Karpouzas GA. Identification and treatment optimization of comorbid depression in rheumatoid arthritis. Rheumatol Ther. 2017;4(2):281\u201391.","journal-title":"Rheumatol Ther"},{"issue":"12","key":"762_CR47","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/acr.23216","volume":"69","author":"H Kim","year":"2017","unstructured":"Kim H, Cui J, Frits M, et al. Fibromyalgia and the prediction of two-year changes in functional status in rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2017;69(12):1871\u20137.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"762_CR48","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10067-010-1584-2","volume":"30","author":"B Strasser","year":"2011","unstructured":"Strasser B, Leeb G, Strehblow C, et al. The effects of strength and endurance training in patients with rheumatoid arthritis. Clin Rheumatol. 2011;30(5):623\u201332.","journal-title":"Clin Rheumatol"},{"issue":"13","key":"762_CR49","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000025019","volume":"100","author":"Z Wen","year":"2021","unstructured":"Wen Z, Chai Y. Effectiveness of resistance exercises in the treatment of rheumatoid arthritis: a meta-analysis. Medicine (Baltimore). 2021;100(13): e25019.","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"762_CR50","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/mr\/roac095","volume":"33","author":"M Torii","year":"2023","unstructured":"Torii M, Itaya T, Minamino H, et al. Management of sarcopenia in patients with rheumatoid arthritis. Mod Rheumatol. 2023;33(3):435\u201340.","journal-title":"Mod Rheumatol"},{"issue":"6","key":"762_CR51","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s11916-012-0298-3","volume":"16","author":"TJ Somers","year":"2012","unstructured":"Somers TJ, Wren AA, Shelby RA. The context of pain in arthritis: self-efficacy for managing pain and other symptoms. Curr Pain Headache Rep. 2012;16(6):502\u20138.","journal-title":"Curr Pain Headache Rep"},{"issue":"3","key":"762_CR52","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3390\/life13030849","volume":"13","author":"Z Nagy","year":"2023","unstructured":"Nagy Z, Szigedi E, Takacs S, Csaszar-Nagy N. The effectiveness of psychological interventions for rheumatoid arthritis (RA): a systematic review and meta-analysis. Life (Basel). 2023;13(3):849. https:\/\/doi.org\/10.3390\/life13030849.","journal-title":"Life (Basel)"},{"issue":"8","key":"762_CR53","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1093\/rheumatology\/kead579","volume":"63","author":"K Sonomoto","year":"2024","unstructured":"Sonomoto K, Nakayamada S, Fujino Y, et al. Biological\/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study. Rheumatology (Oxford). 2024;63(8):2239\u201348.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"762_CR54","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11914-020-00566-7","volume":"18","author":"EM Curtis","year":"2020","unstructured":"Curtis EM, Woolford S, Holmes C, Cooper C, Harvey NC. General and specific considerations as to why osteoporosis-related care is often suboptimal. Curr Osteoporos Rep. 2020;18(1):38\u201346.","journal-title":"Curr Osteoporos Rep"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00762-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00762-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00762-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T10:04:14Z","timestamp":1747389854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00762-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["762"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00762-w","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Koshiro Sonomoto has received speaking fees from AbbVie, Eli Lilly Japan, Gilead Sciences, GlaxoSmithKline, Janssen, Pfizer Japan, UCB Japan, Astellas, Ayumi, Chugai, Taisho, Tanabe Mitsubishi and has received research funding from UCB Japan. Shingo Nakayamada has received consulting fees, speaking fees, lecture fees, and\/or honoraria from AstraZeneca, GlaxoSmithKline, Pfizer, Bristol-Myers, Astellas, Asahi-kasei, AbbVie, Chugai, Sanofi, Eisai, Gilead Sciences, Mitsubishi-Tanabe, Janssen, Eli Lilly, and Ayumi. Yoshiya Tanaka has received speaking fees and\/or honoraria from Eli Lilly, AstraZeneca, AbbVie, Gilead, Chugai, Behringer-Ingelheim, GlaxoSmithKline, Eisai, Taisho, Bristol-Myers, Pfizer, Taiho, received research grants from Mitsubishi-Tanabe, Eisai, Chugai, Taisho. Yoshiya Tanaka is an Editorial Board member of Rheumatology and Therapy. Yoshiya Tanaka was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Hiroaki Tanaka and Atsushi Nagayasu have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study followed the Declaration of Helsinki and was approved by the Ethics Committee of the University of Occupational and Environmental Health School of Medicine (#UOEHCRB21-068). Informed consent was obtained from all participants based on the Ethical Guidelines for Medical and Health Research Involving Human Subjects issued by the Japanese Ministry of Health, Labor and Welfare. Written informed consent was obtained from participants enrolled after April 2015, and written or verbal consent was obtained from others.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}